09:57:42 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-10-31 Kvartalsrapport 2024-Q3
2024-08-08 Kvartalsrapport 2024-Q2
2024-04-25 Kvartalsrapport 2024-Q1
2024-04-05 Ordinarie utdelning REG1V 0.38 EUR
2024-04-04 Årsstämma 2024
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-10 Kvartalsrapport 2023-Q2
2023-04-27 Kvartalsrapport 2023-Q1
2023-03-24 Ordinarie utdelning REG1V 0.36 EUR
2023-03-23 Årsstämma 2023
2023-02-09 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-04 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-11 Ordinarie utdelning REG1V 0.34 EUR
2022-04-08 Årsstämma 2022
2022-02-10 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-05 Kvartalsrapport 2021-Q2
2021-04-23 Kvartalsrapport 2021-Q1
2021-03-18 Ordinarie utdelning REG1V 0.32 EUR
2021-03-17 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-08-06 Kvartalsrapport 2020-Q2
2020-06-09 Ordinarie utdelning REG1V 0.30 EUR
2020-06-08 Årsstämma 2020
2020-04-22 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-04-16 Kvartalsrapport 2019-Q1
2019-03-21 Ordinarie utdelning REG1V 0.28 EUR
2019-03-20 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-06 Kvartalsrapport 2018-Q2
2018-04-20 Kvartalsrapport 2018-Q1
2018-03-21 Ordinarie utdelning REG1V 0.78 EUR
2018-03-20 Årsstämma 2018
2018-02-15 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-08-07 Kvartalsrapport 2017-Q2
2017-05-22 Årsstämma 2017
2017-04-20 Kvartalsrapport 2017-Q1
2017-03-23 Ordinarie utdelning REG1V 0.74 EUR
2017-02-16 Bokslutskommuniké 2016
2016-10-31 Kvartalsrapport 2016-Q3
2016-08-08 Kvartalsrapport 2016-Q2
2016-04-25 Kvartalsrapport 2016-Q1
2016-03-16 Ordinarie utdelning REG1V 0.70 EUR
2016-03-15 Årsstämma 2016
2016-02-15 Bokslutskommuniké 2015
2015-10-27 Kvartalsrapport 2015-Q3
2015-08-10 Kvartalsrapport 2015-Q2
2015-04-24 Kvartalsrapport 2015-Q1
2015-03-20 Ordinarie utdelning REG1V 0.45 EUR
2015-03-19 Årsstämma 2015
2015-02-12 Bokslutskommuniké 2014
2014-10-21 Kvartalsrapport 2014-Q3
2014-08-04 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-03-21 Ordinarie utdelning REG1V 0.30 EUR
2014-03-20 Årsstämma 2014
2014-02-12 Bokslutskommuniké 2013
2013-12-11 Bonusutdelning REG1V 0.3
2013-12-09 Extra Bolagsstämma 2013
2013-10-22 Kvartalsrapport 2013-Q3
2013-08-28 Kapitalmarknadsdag 2013
2013-08-05 Kvartalsrapport 2013-Q2
2013-08-02 Bonusutdelning REG1V 0.12
2013-04-19 Kvartalsrapport 2013-Q1
2013-03-28 Split REG1V 10:1
2013-03-22 Ordinarie utdelning REG1V 0.02 EUR
2013-03-21 Årsstämma 2013
2013-02-08 Bokslutskommuniké 2012
2012-10-19 Kvartalsrapport 2012-Q3
2012-08-06 Kvartalsrapport 2012-Q2
2012-04-19 Kvartalsrapport 2012-Q1
2012-03-29 Ordinarie utdelning REG1V 0.02 EUR
2012-03-28 Årsstämma 2012
2012-02-16 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-08 Kvartalsrapport 2011-Q2
2011-04-27 Kvartalsrapport 2011-Q1
2011-04-01 Ordinarie utdelning REG1V 0.02 EUR
2011-03-31 Årsstämma 2011
2011-02-16 Bokslutskommuniké 2010
2010-04-09 Ordinarie utdelning REG1V 0.01 EUR
2009-04-16 Ordinarie utdelning REG1V 0.02 EUR
2008-04-03 Ordinarie utdelning REG1V 0.04 EUR
2007-04-09 Ordinarie utdelning REG1V 0.01 EUR
2006-03-31 Ordinarie utdelning REG1V 0.00 EUR
2005-04-01 Ordinarie utdelning REG1V 0.00 EUR
2004-03-29 Ordinarie utdelning REG1V 0.00 EUR
2003-03-24 Ordinarie utdelning REG1V 0.00 EUR
2002-04-15 Ordinarie utdelning REG1V 0.00 EUR

Beskrivning

LandFinland
ListaLarge Cap Helsinki
SektorHälsovård
IndustriMedicinteknik
Revenio är verksamt inom medicinteknik. Inom koncernen återfinns forskning och utveckling av tryckmätningsteknik som används vid behandling av ett flertal sjukdomar såsom glaukom, osteoporos, hudcancer samt astma. Verksamhet innehas på global nivå och drivs via flertalet dotterbolag med vardera affärsinriktning. Bolagets huvudkontor ligger i Vantaa.
2023-06-08 16:45:00

Revenio Group Corporation, Stock Exchange Release, June 8, 2023 at 5.45 p.m. (EEST)

The Board of Directors of Revenio Group Corporation has decided, on the basis of the share issue authorization granted to the Board of Directors by the company's Annual General Meeting held on March 23, 2023, to issue shares in a directed share issue without payment to pay the shares from the 2022 earnings period earned by the company’s subsidiary Oculo’s key persons during the performance period 2021-2023 of the share-based incentive scheme.

The arrangement is established to form part of the long-term incentive and commitment program for certain key employees of Oculo. The aim of the arrangement is to support the implementation of the company´s strategy, combine the interests of the shareholders and the participants in order to increase the value and performance of the company in the long-term, to commit participants to the Company after the acquisition. The maximum number of shares in the program is limited. Under the program, shares will be issued for a maximum total value of AUD 1,660,000, calculated at the trading-weighted average price on the closing date April 27, 2021 of the Oculo acquisition. The Arrangement is a three-year performance share plan for the calendar years 2021, 2022 and 2023, respectively.

A total of 1,083 of the company’s treasury shares will be transferred in a directed issue free of charge to persons included in the share-based incentive scheme. After the transfers, the company holds 88,342 treasury shares.

For further information, please contact
CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

Distribution
Nasdaq Helsinki Ltd
Financial Supervisory Authority (FIN-FSA)
Main media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2022, the Group’s net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.